Press Releases


Trulicity® (dulaglutide) is now indicated as an adjunct to diet, exercise, and standard of care therapy to reduce the risk of non-fatal stroke in adults with type 2 diabetes mellitus who have multiple cardiovascular risk factors or established cardiovascu

September 22, 2020

New indication reflects distinct patient population in the REWIND study – people with type 2 diabetes with multiple cardiovascular risks or established cardiovascular disease TORONTO , Sept. 22, 2020 (GLOBE NEWSWIRE) -- On September 11, 2020 , Health Canada approved Trulicity® (dulaglutide) to




Verzenio® Significantly Reduced the Risk of Cancer Recurrence by 25% for People with HR+, HER2- High Risk Early Breast Cancer

September 20, 2020

Tags |  Product

Verzenio in combination with endocrine therapy is the only CDK4 & 6 inhibitor to demonstrate a statistically significant improvement in invasive disease-free survival (IDFS) in early breast cancer   The Phase 3 monarchE trial evaluating the effects of two years of Verzenio treatment added to




CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis

September 18, 2020

Tags |  Product

Positive Opinion is the First Regulatory Action for Baricitinib as an Atopic Dermatitis Medicine INDIANAPOLIS , Sept. 18, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for




Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies

September 17, 2020

Tags |  Corporate

Agreement will significantly increase global supply capacity for Lilly's potential COVID-19 treatments INDIANAPOLIS and THOUSAND OAKS, Calif. , Sept. 17, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) today announced a global antibody manufacturing collaboration to




Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting

September 16, 2020

Tags |  Product

- Primary endpoint of viral load change from baseline at day 11 was met for one of three doses; consistent effects of viral reduction seen at earlier time points   - Rate of hospitalizations and ER visits was 1.7 percent (5/302) for LY-CoV555 versus 6 percent (9/150) for placebo--a 72 percent risk




Lilly Launches Digital Health Open Innovation Challenge to Help Transform Atopic Dermatitis Care

September 15, 2020

Tags |  Corporate

INDIANAPOLIS , Sept. 15, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) has launched an open innovation challenge for individuals and teams across the United States to submit inspiring digital health solutions that can help make life better for people living with atopic dermatitis.




US FDA grants Fast Track designation to Jardiance® (empagliflozin) to improve outcomes following a heart attack

September 15, 2020

Tags |  Product

- FDA Fast Track designation facilitates the development of potential new therapies that treat serious conditions and fulfill an unmet medical need   - This Fast Track designation for empagliflozin emphasizes the urgent need for potential treatments that may improve outcomes following an acute




Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial

September 14, 2020

Tags |  Product

- Study Met Primary Endpoint of Reduction of Time to Recovery   - Additional Analyses Ongoing to Understand Other Clinical Outcome Data   - Lilly's Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Baricitinib Continues INDIANAPOLIS , Sept.




Lilly to Participate in Cantor Fitzgerald Virtual Global Healthcare Conference

September 11, 2020

Tags |  Financial

INDIANAPOLIS , Sept. 11, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Cantor Fitzgerald Virtual Global Healthcare Conference on Thursday, September 17, 2020 . Joshua Smiley , senior vice president and Lilly 's chief financial officer, will participate in a virtual




Lilly to Participate in Morgan Stanley Global Healthcare Conference

September 11, 2020

Tags |  Financial

INDIANAPOLIS , Sept. 11, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, September 16, 2020 . Joshua Smiley , senior vice president and Lilly 's chief financial officer, will participate in a virtual fireside